Organon’s VTAMA Cream Shows Early Efficacy Across All Age Groups in Atopic Dermatitis Trials — Organon & Co.

Event summary

Organon presented pooled Phase 3 data at the 2026 Society for Pediatric Dermatology Annual Meeting showing VTAMA cream’s early and consistent improvements in atopic dermatitis patients across all age groups.
The analysis included 813 patients aged 2 years and older, with 80.4% being pediatric patients.
VTAMA demonstrated significant skin clearance (vIGA-AD response) at week 8 across all age groups, with the highest efficacy in the 2–6 years group (56.3% vs. 11.8%).
The most common adverse events were folliculitis, headache, and nasopharyngitis, generally mild or moderate in severity.

The big picture

Organon’s VTAMA cream is positioned as a first-in-class aryl hydrocarbon receptor (AhR) agonist, offering a steroid-free treatment option for atopic dermatitis. The consistent efficacy demonstrated across all age groups reinforces its strategic value in a market where pediatric patients represent a significant portion of cases. The American Academy of Dermatology’s strong recommendations further bolster VTAMA’s standing as a key player in dermatological care.

What we're watching

Market Positioning: Whether VTAMA can sustain its position as a leading nonsteroidal treatment option for atopic dermatitis in both adults and pediatric patients.
Regulatory Approval: The pace at which additional regulatory approvals may expand VTAMA’s indications or age range.
Competitive Dynamics: How competitors will respond to Organon’s strengthened clinical data, particularly in the pediatric market.